A freeze‐dried platelet‐derived hemostatic agent improves hemostasis in patients with severe thrombocytopenia before and after standard platelet transfusion: Studies ex vivo in the total thrombus‐formation analysis system 01
Transfusion · 2026-05 · 66 (5) · 987-997
DOI: 10.1111/trf.70153 ↗At a glance
Journal article in Transfusion, published online on 2026-03-06. Written by S Samanbar and 11 co-authors. Institution: Hematopathology, Pathology Department, Centre de Diagnòstic Biomèdic (CDB), Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer…. Major MEDLINE topics: Platelet Transfusion, Thrombocytopenia, Hemostasis, Blood Platelets. 48 references. Funded by: Agència de Gestió d'Ajuts Universitaris i de Recerca, Cellphire Therapeutics, Zacros (Fujimori Kogyo Co., Ltd., Japan).
Abstract (original language)
Background Lyophilized platelet products have emerged as potential alternatives to standard platelet concentrates (PCs), especially amid shortages or in critical bleeding scenarios. However, assessing their hemostatic efficacy is challenging. The total thrombus‐formation analysis system 01 (T‐TAS 01), a microfluidic‐based technology, provides a standardized approach for evaluating hemostasis in blood samples with low platelet counts. Study Design and Methods We evaluated the hemostatic performance of a platelet‐derived hemostatic product (FPH) using T‐TAS 01. FPH was added ex vivo to blood samples from thrombocytopenic oncohematological patients (platelet count
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Hematopathology, Pathology Department, Centre de Diagnòstic Biomèdic (CDB), Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
- Hematology Department, Instituto del Cáncer y Enfermedades de la Sangre (ICAMS), Hospital Clinic, Barcelona, Spain.
- Cellphire Therapeutics, Inc., Rockville, Maryland, USA.
- KA Bioscience Consultants, LLC, Westfield, Indianapolis, USA.
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Apheresis and Cellular Therapy Unit, Hemotherapy and Hemostasis Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Funding
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- Cellphire Therapeutics
- Zacros (Fujimori Kogyo Co., Ltd., Japan)
Cite
APA
Samanbar, S., Piñeyroa, J. A., Moreno-Castaño, A. B., Molina, P., Pino, M., Torramade-Moix, S., Martinez-Sanchez, J., Moskowitz, K., Koller, T., Lozano, M., Escolar, G., & Diaz-Ricart, M. (2026). A freeze‐dried platelet‐derived hemostatic agent improves hemostasis in patients with severe thrombocytopenia before and after standard platelet transfusion: Studies ex vivo in the total thrombus‐formation analysis system 01. Transfusion, 66(5), 987-997. https://doi.org/10.1111/trf.70153
Vancouver
Samanbar S, Piñeyroa JA, Moreno-Castaño AB, Molina P, Pino M, Torramade-Moix S, et al. A freeze‐dried platelet‐derived hemostatic agent improves hemostasis in patients with severe thrombocytopenia before and after standard platelet transfusion: Studies ex vivo in the total thrombus‐formation analysis system 01. Transfusion. 2026;66(5):987-997. doi:10.1111/trf.70153
BibTeX
@article{Samanbar2026,
author = {Samanbar, S and Piñeyroa, J A and Moreno-Castaño, A B and Molina, P and Pino, M and Torramade-Moix, S and Martinez-Sanchez, J and Moskowitz, K and Koller, T and Lozano, M and Escolar, G and Diaz-Ricart, M},
title = {A freeze‐dried platelet‐derived hemostatic agent improves hemostasis in patients with severe thrombocytopenia before and after standard platelet transfusion: Studies ex vivo in the total thrombus‐formation analysis system 01},
journal = {Transfusion},
year = {2026},
volume = {66},
number = {5},
pages = {987--997},
doi = {10.1111/trf.70153}
}
EUVIMED